Heart disease in diabetic patients

Seminars in Nephrology

Volumn 25, Issue 6, 2005, Pages 372-378

  Toto, Robert D ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Albuminuria heart failure; Coronary artery disease; Diabetics; Kidney disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRON; LIPID; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PRAVASTATIN; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ANEMIA; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING CESSATION; STROKE;

EID: 27844590364     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2005.05.005     Document Type: Article

References (55)

1. E.M. Damsgaard, A. Froland, O.D. Jorgensen Eight to nine year mortality in known non-insulin dependent diabetics and controls Kidney Int 41 1992 731 735
2. B.E. Klein, R. Klein, P.E. McBride Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes Wisconsin epidemiologic study of diabetic retinopathy Arch Intern Med 164 2004 1917 1924
3. K. Borch-Johnsen, K. Andersen, T. Deckert The impact of proteinuria on the relative mortality in patients with type I diabetes mellitus Diabetologia 28 1985 590 596
4. R. Giansanti, R.A. Rabini, F. Romagnoli Coronary heart disease, type 2 diabetes mellitus and cardiovascular disease risk factors A study on a middle-aged and elderly population Arch Gerontol Geriatr 29 1999 175 181
5. T. Almdal, H. Scharling, J.S. Jensen The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death a population-based study of 13,000 men and women with 20 years of follow-up Arch Intern Med 164 2004 1422 1426
6. G. Marchesini, G. Forlani, F. Cerrelli WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes Diabet Med 21 2004 383 387
7. H.S. Lim, R.J. MacFadyen, G.Y. Lip Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart Arch Intern Med 164 2004 1737 1748
8. H.M. Colhoun, D.J. Betteridge, P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) Multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
9. W.H. Wilson Tang, A. Maroo, J.B. Young Ischemic heart disease and congestive heart failure in diabetic patients Med Clin North Am 88 2004 1037 1061
10. R. Danielsen, J.E. Nordrehaug, H. Vik-Mo Left ventricular diastolic function in young long-term type 1 (insulin-dependent) diabetic men during exercise assessed by digitized echocardiography Eur Heart J 9 1988 395 402
11. K.M. Borow, J.B. Jaspan, K.A. Williams Myocardial mechanics in young adult patients with diabetes mellitus Effects of altered load, inotropic state and dynamic exercise J Am Coll Cardiol 15 1990 1508 1517
12. T. Unger, D. Ganten, R. Lang Is tissue converting enzyme inhibitor a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneous hypertensive rats J Cardiovasc Pharmacol 6 1984 872 880
13. R.H. Unger, L. Orci Lipoapoptosis Its mechanism and its diseases Biochim Biophys Acta 1585 2004 202 212
14. L.D. Monti, C. Landoni, E. Setola Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in type 2 diabetic patients Am J Physiol 287 2004 H1225 H1231
15. E. Lurbe, J. Redon, A. Kesani Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes N Engl J Med 347 2002 797 805
16. M. Quinones, M. Hernandez-Pampaloni, H. Schelbert Coronary vasomotor abnormalities in insulin-resistant individuals Ann Intern Med 140 2004 700 708
17. G.L. Bakris, M. Williams, L. Dworkin National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Preserving renal function in adults with hypertension and diabetes A consensus approach Am J Kidney Dis 36 2000 646 661
18. F. El Atat, S.I. McFarlane, J.R. Sowers Diabetes, hypertension, and cardiovascular derangements Pathophysiology and management Curr Hypertens Rep 6 2004 215 223
19. K. Wachtell, H. Ibsen, M.H. Olsen Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy The LIFE study Ann Intern Med 139 2003 901 906
20. I. Saito, A.R. Folsom, F.L. Brancati Nontraditional risk factors for coronary heart disease incidence among persons with diabetes The Atherosclerosis Risk in Communities (ARIC) study Ann Intern Med 133 2000 81 91
21. W.M. McClellan, W.D. Flanders, R.D. Langston Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals A population-based study J Am Soc Nephrol 13 2002 1928 1936
22. D.S. Silverberg, D. Wexler, M. Blum The interaction between heart failure, renal failure and anemia - the cardio-renal anemia syndrome Blood Purif 22 2004 277 284
23. D.S. Silverberg, D. Wexler, M. Blum The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations J Am Coll Cardiol 35 2000 1737 1744
24. A. Levin Anaemia in the patient with renal insufficiency Documenting the impact and reviewing treatment strategies Nephrol Dial Transplant 14 1999 292 295
25. A. Levin Anemia and left ventricular hypertrophy in chronic kidney disease populations A review of the current state of knowledge Kidney Int 61 suppl 2002 35 38
26. G.M. London, B. Pannier, A.P. Guerin Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis Follow-up of an interventional study J Am Soc Nephrol 12 2001 2759 2767
27. G.M. London, A.P. Guerin, S.J. Marchais Pathophysiology of left ventricular hypertrophy in dialysis patients Blood Purif 12 1994 277 283
28. G.M. London, F. Fabiani, S.J. Marchais Uremic cardiomyopathy An inadequate left ventricular hypertrophy Kidney Int 31 1987 973 980
29. S.M. Haffner, C.M. Alexander, T.J. Cook Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels Subgroup analyses in the Scandinavian Simvastatin Survival Study Arch Intern Med 159 1999 2661 2667
30. T. Kazumi, G. Yoshino, A. Ohki Hyogo Simvastatin Study Group Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors Horm Metab Res 27 1995 239 243
31. MRC/BHF Heart Protection Study: Cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 2002 7 22
32. P.S. Sever, B. Dahlof, N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) A multicentre randomised controlled trial Lancet 361 2003 1149 1158
33. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38 BMJ 317 1998 703 713
34. A.I. Adler, I.M. Stratton, H.A. Neil Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36) Prospective observational study BMJ 321 2000 412 419
35. HOPE Trial Investigators Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus Results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
36. B. Dahlof, R.B. Devereux, S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) A randomised trial against atenolol Lancet 359 2002 995 1003
37. P. Gaede, P. Vedel, N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
38. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
39. C. Wanner, V. Krane, G. Ruf Die Deutsche Diabetes Dialyse Studie Investigators Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis Kidney Int Suppl 71 1999 S222 S226
40. C. Baigent, M. Landry Study of Heart and Renal Protection (SHARP) Kidney Int 63 suppl 2003 S207 S210
41. T.C. Mix, R.M. Brenner, M.E. Cooper Rationale - Trial to reduce cardiovascular events with Aranesp Therapy (TREAT) evolving the management of cardiovascular risk in patients with chronic kidney disease AM Heart J 149 3 2005 408 413
42. G.L. Bakris, M.R. Weir, M. Secic Differential effects of calcium antagonist subclasses on markers of nephropathy progression Kidney Int 65 2004 1991 2002
43. A.C. Smith, R. Toto, G.L. Bakris Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy Kidney Int 54 1998 889 896
44. B. Pitt, W. Remme, F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
45. B. Pitt, F. Zannad, W.J. Remme Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
46. D.N. Juurlink, M.M. Mamdani, D.S. Lee Rates of hyperkalemia after publication of the randomized aldactone evaluation study N Engl J Med 351 2004 543 551
47. P. Raskin Diabetes control and complications trial Implications for the treatment of diabetes mellitus 1994 The University of Texas SW Medical Center, Medical Grand Rounds, Dallas, Texas Texas
48. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
49. UKPDS Glucose Investigators UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
50. American Diabetes Association Standards of medical care for patients with diabetes mellitus Diabetes Care 26 2003 33S 35S
51. S.M. Grundy, J.I. Cleeman, C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
52. L. Corradi, A. Zoppi, F. Tettamanti Association between smoking and micro-albuminuria in hypertensive patients with type 2 diabetes mellitus J Hypertens 11 1993 S190 S191
53. M.A. Gall, P. Hougaard, K. Borch-Johnsen Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus Prospective, observational study BMJ 314 1997 783 788
54. P. Hovind, P. Rossing, L. Tarnow Smoking and progression of diabetic nephropathy in type 1 diabetes Diabetes Care 26 2003 911 916
55. P.T. Sawicki, U. Didjurgeit, I. Muhlhauser Smoking is associated with progression of diabetic nephropathy Diabetes Care 17 1994 126 131